{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:41:14Z","timestamp":1791996074935,"version":"4.4.0"},"reference-count":41,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The objective of this retrospective study was to compare the rates of treatment failure, which was a composite of clinical and microbiologic failure, of patients receiving vancomycin and a \u03b2-lactam to those receiving vancomycin only for methicillin-resistant\n            <jats:named-content content-type=\"genus-species\">Staphylococcus aureus<\/jats:named-content>\n            (MRSA) bacteremia. Patients 16 to 89 years of age with MRSA bacteremia admitted to a university-affiliated hospital from 1 January 2014 to 31 December 2016 were screened for study inclusion. Patients were eligible if they received &gt;48 h of vancomycin and a \u03b2-lactam (combination group) or vancomycin only (standard group) within 48 h after bacteremia onset. A total of 182 patients were screened: 47 were included in the standard group, and 63 were in the combination group. The combination group had a higher baseline body mass index (29.2 \u00b1 8.0 kg\/m\n            <jats:sup>2<\/jats:sup>\n            versus 25.8 \u00b1 7.1 kg\/m\n            <jats:sup>2<\/jats:sup>\n            ,\n            <jats:italic>P<\/jats:italic>\n            = 0.022), acute physiologic assessment and chronic health evaluation-II (APACHE-II) score (median [interquartile range], 21 [15 to 26] versus 16 [10 to 22],\n            <jats:italic>P<\/jats:italic>\n            = 0.003), and incidence of septic shock (31.8% versus 14.9%,\n            <jats:italic>P<\/jats:italic>\n            = 0.047). Using multivariate analysis, combination therapy was the only variable that decreased treatment failures (odds ratio [95% confidence interval], 0.337 [0.142 to 0.997]), while vancomycin MIC &gt; 1 mg\/liter and male gender increased treatment failures (4.018 [1.297 to 12.444] and 2.971 [1.040 to 8.488], respectively). The 30-day mortality rates (15.0% versus 14.9%,\n            <jats:italic>P<\/jats:italic>\n            = 1.000) and the incidence of adverse drug events (19.1% versus 23.4%,\n            <jats:italic>P<\/jats:italic>\n            = 0.816) were not statistically different between the combination and standard groups. Combination therapy of vancomycin with a \u03b2-lactam led to significantly fewer treatment failures than vancomycin monotherapy for MRSA bacteremia.\n          <\/jats:p>","DOI":"10.1128\/aac.01554-17","type":"journal-article","created":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T16:54:58Z","timestamp":1510592098000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":40,"title":["Outcomes of Vancomycin plus a \u03b2-Lactam versus Vancomycin Only for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia"],"prefix":"10.1128","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7980-2852","authenticated-orcid":false,"given":"James","family":"Truong","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Veillette","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve C.","family":"Forland","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, California, USA"},{"name":"Department of Pharmacy, Loma Linda University Medical Center, Loma Linda, California, USA"},{"name":"Loma Linda University School of Medicine, Loma Linda, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080434"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn372"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.17.1861"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1807.101371"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-279"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00485-11"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02800-14"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04677-14"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq146"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.05287-11"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00113-08"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1215-2"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp319"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1086\/606027"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00380-13"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053783"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit112"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir764"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2015.09.017"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/595686"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.07.005"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks006"},{"key":"e_1_3_2_24_2","volume-title":"Linezolid (package insert)","author":"Pfizer","year":"2013","unstructured":"Pfizer. 2013. Linezolid (package insert). Pfizer, New York, NY."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/338403"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1596"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130474"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12062"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.06.027"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0042103"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05473-11"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01204-13"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ808"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw709"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1179\/1973947815Y.0000000076"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170236"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03679.x"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2010.09.029"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc2872"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu583"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31827e83af"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e318289ff1e"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01554-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01554-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:09:12Z","timestamp":1645477752000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01554-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1128\/AAC.01554-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.01554-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"2017-08-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01554-17"}}